Factors of Early Recurrence After Resection for Intrahepatic Cholangiocarcinoma
Corresponding Author
Alexandra Nassar
Department of Hepatobiliary, Pancreatic and Endocrine Surgery, Cochin Hospital, Assistance publique-hôpitaux de Paris, University of Paris, 27 rue du Faubourg Saint-Jacques, 75014 Paris, France
[email protected]Search for more papers by this authorStylianos Tzedakis
Department of Hepatobiliary, Pancreatic and Endocrine Surgery, Cochin Hospital, Assistance publique-hôpitaux de Paris, University of Paris, 27 rue du Faubourg Saint-Jacques, 75014 Paris, France
Search for more papers by this authorRémy Sindayigaya
Department of Hepatobiliary, Pancreatic and Endocrine Surgery, Cochin Hospital, Assistance publique-hôpitaux de Paris, University of Paris, 27 rue du Faubourg Saint-Jacques, 75014 Paris, France
Search for more papers by this authorChristian Hobeika
Department of Hepato-Pancreato-Biliary Surgery and Liver Transplantation, Beaujon Hospital, Assistance publique-hôpitaux de Paris, University of Paris, Clichy, France
Search for more papers by this authorUgo Marchese
Department of Hepatobiliary, Pancreatic and Endocrine Surgery, Cochin Hospital, Assistance publique-hôpitaux de Paris, University of Paris, 27 rue du Faubourg Saint-Jacques, 75014 Paris, France
Search for more papers by this authorJulie Veziant
Department of Hepatobiliary, Pancreatic and Endocrine Surgery, Cochin Hospital, Assistance publique-hôpitaux de Paris, University of Paris, 27 rue du Faubourg Saint-Jacques, 75014 Paris, France
Search for more papers by this authorTatiana Codjia
Department of Hepato-Pancreato-Biliary Surgery and Liver Transplantation, Beaujon Hospital, Assistance publique-hôpitaux de Paris, University of Paris, Clichy, France
Search for more papers by this authorAurélie Beaufrère
Department of Pathology, Beaujon Hospital, Assistance publique-hôpitaux de Paris, University of Paris, Clichy, France
Search for more papers by this authorAlix Dhote
Department of Hepatobiliary, Pancreatic and Endocrine Surgery, Cochin Hospital, Assistance publique-hôpitaux de Paris, University of Paris, 27 rue du Faubourg Saint-Jacques, 75014 Paris, France
Search for more papers by this authorMarie Strigalev
Department of Hepatobiliary, Pancreatic and Endocrine Surgery, Cochin Hospital, Assistance publique-hôpitaux de Paris, University of Paris, 27 rue du Faubourg Saint-Jacques, 75014 Paris, France
Search for more papers by this authorFrançois Cauchy
Department of Hepato-Pancreato-Biliary Surgery and Liver Transplantation, Beaujon Hospital, Assistance publique-hôpitaux de Paris, University of Paris, Clichy, France
Search for more papers by this authorDavid Fuks
Department of Hepatobiliary, Pancreatic and Endocrine Surgery, Cochin Hospital, Assistance publique-hôpitaux de Paris, University of Paris, 27 rue du Faubourg Saint-Jacques, 75014 Paris, France
Search for more papers by this authorCorresponding Author
Alexandra Nassar
Department of Hepatobiliary, Pancreatic and Endocrine Surgery, Cochin Hospital, Assistance publique-hôpitaux de Paris, University of Paris, 27 rue du Faubourg Saint-Jacques, 75014 Paris, France
[email protected]Search for more papers by this authorStylianos Tzedakis
Department of Hepatobiliary, Pancreatic and Endocrine Surgery, Cochin Hospital, Assistance publique-hôpitaux de Paris, University of Paris, 27 rue du Faubourg Saint-Jacques, 75014 Paris, France
Search for more papers by this authorRémy Sindayigaya
Department of Hepatobiliary, Pancreatic and Endocrine Surgery, Cochin Hospital, Assistance publique-hôpitaux de Paris, University of Paris, 27 rue du Faubourg Saint-Jacques, 75014 Paris, France
Search for more papers by this authorChristian Hobeika
Department of Hepato-Pancreato-Biliary Surgery and Liver Transplantation, Beaujon Hospital, Assistance publique-hôpitaux de Paris, University of Paris, Clichy, France
Search for more papers by this authorUgo Marchese
Department of Hepatobiliary, Pancreatic and Endocrine Surgery, Cochin Hospital, Assistance publique-hôpitaux de Paris, University of Paris, 27 rue du Faubourg Saint-Jacques, 75014 Paris, France
Search for more papers by this authorJulie Veziant
Department of Hepatobiliary, Pancreatic and Endocrine Surgery, Cochin Hospital, Assistance publique-hôpitaux de Paris, University of Paris, 27 rue du Faubourg Saint-Jacques, 75014 Paris, France
Search for more papers by this authorTatiana Codjia
Department of Hepato-Pancreato-Biliary Surgery and Liver Transplantation, Beaujon Hospital, Assistance publique-hôpitaux de Paris, University of Paris, Clichy, France
Search for more papers by this authorAurélie Beaufrère
Department of Pathology, Beaujon Hospital, Assistance publique-hôpitaux de Paris, University of Paris, Clichy, France
Search for more papers by this authorAlix Dhote
Department of Hepatobiliary, Pancreatic and Endocrine Surgery, Cochin Hospital, Assistance publique-hôpitaux de Paris, University of Paris, 27 rue du Faubourg Saint-Jacques, 75014 Paris, France
Search for more papers by this authorMarie Strigalev
Department of Hepatobiliary, Pancreatic and Endocrine Surgery, Cochin Hospital, Assistance publique-hôpitaux de Paris, University of Paris, 27 rue du Faubourg Saint-Jacques, 75014 Paris, France
Search for more papers by this authorFrançois Cauchy
Department of Hepato-Pancreato-Biliary Surgery and Liver Transplantation, Beaujon Hospital, Assistance publique-hôpitaux de Paris, University of Paris, Clichy, France
Search for more papers by this authorDavid Fuks
Department of Hepatobiliary, Pancreatic and Endocrine Surgery, Cochin Hospital, Assistance publique-hôpitaux de Paris, University of Paris, 27 rue du Faubourg Saint-Jacques, 75014 Paris, France
Search for more papers by this authorAbstract
Background
Two-thirds of patients undergoing liver resection for intrahepatic cholangiocarcinoma experience recurrence after surgery. Our aim was to identify factors associated with early recurrence after resection for intrahepatic cholangiocarcinoma.
Methods
Patients with intrahepatic cholangiocarcinoma undergoing curative intent resection (complete resection and lymphadenectomy) were included in two centers between 2005 and 2021 and were divided into three groups: early recurrence (< 12 months after resection), delayed recurrence (> 12 months), and no recurrence. Patients experiencing early (< 90 days) postoperative mortality were excluded.
Results
Among 120 included patients, 44 (36.7%) experienced early recurrence, 24 (20.0%) experienced delayed recurrence, and 52 (43.3%) did not experience recurrence after a median follow-up of 59 months (IQR: 26-113). The median recurrence-free survival was 16 months (95% CI: 9.6–22.4). Median overall survival was 55 months (95% CI: 45.7–64.3), while it was 25 months for patients with early recurrence (p < 0.001). Patients with early recurrence had significantly larger tumors (59.1% of tumors > 70 mm in early vs. 58.3% in delayed vs. 26.9% in no recurrence group, p = 0.002), multiple lesions (65.9% vs. 29.2% vs. 11.5%, p < 0.001), and positive lymph nodes (N +) (38.6% vs. 37.5% vs. 11.5%, p = 0.005). In multivariable analysis, presence of multiple lesions (OR: 9.324; 95% CI: 3.051–28.489; p < 0.001) and positive lymph nodes (OR: 3.307. 95% CI: 1.001–11.011. p = 0.05) were associated with early recurrence.
Conclusion
Early recurrence after curative resection of intrahepatic cholangiocarcinoma is frequent and is associated with the presence of multiple lesions and positive lymph nodes, raising the question of surgery's futility in this context.
References
- 1Lepage C, Cottet V, Chauvenet M et al. Trends in the incidence and management of biliary tract cancer: a French population-based study. J Hepatol (2011) 54(2): 306–31010.1016/j.jhep.2010.06.039
- 2Wu L, Tsilimigras DI, Paredes AZ et al. Trends in the incidence, treatment and outcomes of patients with intrahepatic cholangiocarcinoma in the USA: facility type is associated with margin status, use of lymphadenectomy and overall survival. World J Surg (2019) 43(7): 1777–178710.1007/s00268-019-04966-430820734
- 3Farges O, Fuks D, Boleslawski E et al. Influence of surgical margins on outcome in patients with intrahepatic cholangiocarcinoma: a multicenter study by the AFC-IHCC-2009 study group. Ann Surg (2011) 254(5): 824–82910.1097/SLA.0b013e318236c21d
- 4Doussot A, Jarnagin WR, Azoulay D et al. Improving actual survival after hepatectomy for intrahepatic cholangiocarcinoma-still a long way to go. Hepatobiliary Surg Nutr (2019) 8(2): 161–16310.21037/hbsn.2018.11.21
- 5Reames BN, Ejaz A, Koerkamp BG et al. Impact of major vascular resection on outcomes and survival in patients with intrahepatic cholangiocarcinoma: a multi-institutional analysis. J Surg Oncol (2017) 116(2): 133–13910.1002/jso.24633
- 6Sutton TL, Billingsley KG, Walker BS et al. Neoadjuvant chemotherapy is associated with improved survival in patients undergoing hepatic resection for intrahepatic cholangiocarcinoma. Am J Surg (2021) 221(6): 1182–118710.1016/j.amjsurg.2021.02.029
- 7Primrose JN, Fox RP, Palmer DH et al. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. Lancet Oncol (2019) 20(5): 663–67310.1016/S1470-2045(18)30915-X
- 8Doussot A, Gonen M, Wiggers JK et al. Recurrence patterns and disease-free survival after resection of intrahepatic cholangiocarcinoma: preoperative and postoperative prognostic models. J Am Coll Surg (2016) 223(3): 493–505.e210.1016/j.jamcollsurg.2016.05.019
- 9Hu L-S, Zhang X-F, Weiss M et al. Recurrence patterns and timing courses following curative-intent resection for intrahepatic cholangiocarcinoma. Ann Surg Oncol (2019) 26(8): 2549–255710.1245/s10434-019-07353-4
- 10Valle J, Wasan H, Palmer DH et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med (2010) 362(14): 1273–128110.1056/NEJMoa0908721
- 11Pang YY The Brisbane 2000 terminology of liver anatomy and resections. HPB (2000) 2: 333–33910.1016/S1365-182X(17)30755-4
10.1016/S1365-182X(17)30755-4 Google Scholar
- 12Dindo D, Demartines N, Clavien P-A Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg (2004) 240(2): 205–21310.1097/01.sla.0000133083.54934.ae
- 13Rahbari NN, Garden OJ, Padbury R et al. Posthepatectomy liver failure: a definition and grading by the international study group of liver surgery (ISGLS). Surgery (2011) 149(5): 713–72410.1016/j.surg.2010.10.001
- 14Koch M, Garden OJ, Padbury R et al. Bile leakage after hepatobiliary and pancreatic surgery: a definition and grading of severity by the international study group of liver surgery. Surgery (2011) 149(5): 680–68810.1016/j.surg.2010.12.002
- 15Malka D, Bernardini D, Boudjema K, et al (2019) Cancer des voies biliaires. TNCD
- 16Edeline J, Benabdelghani M, Bertaut A et al. Gemcitabine and oxaliplatin chemotherapy or surveillance in resected biliary tract cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): a randomized phase III study. J Clin Oncol (2019) 37(8): 658–66710.1200/JCO.18.00050
- 17Wang C, Pang S, Si-Ma H et al. Specific risk factors contributing to early and late recurrences of intrahepatic cholangiocarcinoma after curative resection. World J Surg (2019) 17(1): 210.1186/s12957-018-1540-1
10.1186/s12957-018-1540-1 Google Scholar
- 18Bridgewater J, Galle PR, Khan SA et al. Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. J Hepatol (2014) 60(6): 1268–128910.1016/j.jhep.2014.01.021
- 19Zhang X-F, Beal EW, Bagante F et al. Early versus late recurrence of intrahepatic cholangiocarcinoma after resection with curative intent. Br J Surg (2018) 105(7): 848–85610.1002/bjs.10676
- 20Portolani N, Coniglio A, Ghidoni S et al. Early and late recurrence after liver resection for hepatocellular carcinoma: prognostic and therapeutic implications. Ann Surg (2006) 243(2): 229–23510.1097/01.sla.0000197706.21803.a1
- 21Valverde A, Bonhomme N, Farges O et al. Resection of intrahepatic cholangiocarcinoma: a Western experience. J Hepatobiliary Pancreat Surg (1999) 6(2): 122–12710.1007/s005340050094
- 22Addeo P, Jedidi I, Locicero A et al. Prognostic impact of tumor multinodularity in intrahepatic cholangiocarcinoma. J Gastrointest Surg (2019) 23(9): 1801–180910.1007/s11605-018-4052-y
- 23Xue R, Li R, Guo H et al. Variable intra-tumor genomic heterogeneity of multiple lesions in patients with hepatocellular carcinoma. Gastroenterology (2016) 150(4): 998–100810.1053/j.gastro.2015.12.033
- 24Bagante F, Spolverato G, Merath K et al. Intrahepatic cholangiocarcinoma tumor burden: a classification and regression tree model to define prognostic groups after resection. Surgery (2019) 166(6): 983–99010.1016/j.surg.2019.06.005
- 25Sposito C, Droz Dit Busset M, Virdis M et al. The role of lymphadenectomy in the surgical treatment of intrahepatic cholangiocarcinoma: a review. Eur J Surg Oncol (2021) 10.1016/j.ejso.2021.08.00934412956
- 26Shimada M, Yamashita Y, Aishima S et al. Value of lymph node dissection during resection of intrahepatic cholangiocarcinoma. Br J Surg (2001) 88(11): 1463–146610.1046/j.0007-1323.2001.01879.x
- 27Noji T, Kondo S, Hirano S et al. Computed tomography evaluation of regional lymph node metastases in patients with biliary cancer. Br J Surg (2008) 95(1): 92–9610.1002/bjs.5920
- 28Songthamwat M, Chamadol N, Khuntikeo N et al. Evaluating a preoperative protocol that includes magnetic resonance imaging for lymph node metastasis in the cholangiocarcinoma screening and care program (CASCAP) in Thailand. World J Surg Oncol (2017) 15(1): 17610.1186/s12957-017-1246-9
10.1186/s12957-017-1246-9 Google Scholar
- 29Hobeika C, Cauchy F, Fuks D et al. Laparoscopic versus open resection of intrahepatic cholangiocarcinoma: nationwide analysis. Br J Surg (2021) 108(4): 419–42610.1093/bjs/znaa110
- 30Bagante F, Spolverato G, Weiss M et al. Defining Long-Term survivors following resection of intrahepatic cholangiocarcinoma. J Gastrointest Surg (2017) 21(11): 1888–189710.1007/s11605-017-3550-7
- 31Jutric Z, Johnston WC, Hoen HM et al. Impact of lymph node status in patients with intrahepatic cholangiocarcinoma treated by major hepatectomy: a review of the national cancer database. HPB (2016) 18(1): 79–8710.1016/j.hpb.2015.07.006
- 32Akateh C, Ejaz AM, Pawlik TM et al. Neoadjuvant treatment strategies for intrahepatic cholangiocarcinoma. World J Hepatol (2020) 12(10): 693–70810.4254/wjh.v12.i10.693
